Domain Not Resolving

HSTS

DNSSEC

jQuery CDN

Microsoft

COVID-19

Microsoft Azure

Mobile Optimized

Drupal

Microsoft Azure US East Region

Co-Founder

Brad Geddes

Director of Lab Informatics

Alexander Thomson

Business Management

Andrew Anzalone

Associate Director, Data Management

Angelo Scarsella

Sr Director, Cell Therapy Process Development & Head of CMC Portfolio Management

Barrett Nehilla

Associate Medical Director, Clinical Development

Bradley Martin, MD, PhD

Director, Clinical Development Operations

Briana Deary

Senior Director Financial Planning Analysis

Charley Maggs

Operations

Christopher Hill

Director of Accounting

Courtney Turner

Stephen Knight

Robert Nelsen

John Evans

Keith M. Gottesdiener

David Schenkein

Ann L. Lee

Chief Technical Officer

Jeremy Duffield

Chief Scientific Officer

Allan Reine

Chief Financial Officer

President & Chief Executive Office

Co-founder

Medical Public Companies

East Coast Companies With More Than 100 Employees (Top 10K)

Massachusetts Companies With Less Than $1B in Revenue (Top 10K)

New England Companies With Less Than $50M in Revenue (Top 10K)

Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.

Bristol-Myers Squibb

Corporate Round - Prime Medicine

Cystic Fibrosis Foundation

Funding Round - Prime Medicine

Series B - Prime Medicine

ARCH Venture Partners

F-Prime Capital

Google Ventures

Series A - Prime Medicine

Cambridge

Massachusetts

United States

North America

Prime Medicine

Prime Medicine outlines plans for gene editing pipeline

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Prime Medicine soars as it inks research collab with BMS

Bristol, Prime Medicine in deal to develop T-cell therapies

Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley

Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates (NASDAQ:PRME)

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

Germany

Europe

Italy

India

Asia

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 11:24 AM	be8e46fb
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 11:24 AM	63f9c5e0
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	1b19acb8
crunchbase profile	general	Oct 29, 2024 6:58 AM	6974b639
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	3373431d
peers	general
news basic	general	Mar 8, 2024 11:24 AM	d1015e8e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:PRIMEMEDICINE

Prime Medicine, Inc.

Last Close

2.99

21/11 19:30

Market Cap

666.17M

Beta: -

Volume Today

688.15K

Avg: -